pipobroman has been researched along with Leucocythaemia in 14 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 9.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 5.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 5.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| "The risk of major thrombosis is higher in ET patients aged more than 60 ys." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| " All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value <50% in males and <45% in females)." | 1.30 | Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). ( Avvisati, G; Cosenza, M; Latagliata, R; Malagnino, F; Montefusco, E; Petti, MC; Spadea, A; Spadea, T, 1998) |
| " Relapses occurred in 30% of the cases but responded to pipobroman at the initial high dosage level." | 1.26 | [Management of polycythaemia with pipobroman]. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Perreau-Boutet, MC; Stachowiak, J, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiladjian, JJ | 3 |
| Gardin, C | 1 |
| Renoux, M | 1 |
| Bruno, F | 1 |
| Bernard, JF | 2 |
| De Sanctis, V | 1 |
| Mazzucconi, MG | 1 |
| Spadea, A | 2 |
| Alfò, M | 1 |
| Mancini, M | 1 |
| Bizzoni, L | 1 |
| Peraino, M | 1 |
| Mandelli, F | 1 |
| Passamonti, F | 1 |
| Rumi, E | 1 |
| Malabarba, L | 1 |
| Arcaini, L | 1 |
| Orlandi, E | 1 |
| Brusamolino, E | 1 |
| Pascutto, C | 1 |
| Cazzola, M | 1 |
| Lazzarino, M | 1 |
| Rain, JD | 2 |
| Briere, J | 3 |
| Chomienne, C | 1 |
| Fenaux, P | 1 |
| Perreau-Boutet, MC | 1 |
| Najman, A | 1 |
| Stachowiak, J | 1 |
| Parlier, Y | 1 |
| Gorin, NC | 1 |
| Duhamel, G | 1 |
| Boivin, P | 1 |
| Barbui, T | 1 |
| Finazzi, G | 1 |
| Dupuy, E | 1 |
| Petti, MC | 1 |
| Avvisati, G | 1 |
| Spadea, T | 1 |
| Latagliata, R | 1 |
| Montefusco, E | 1 |
| Cosenza, M | 1 |
| Malagnino, F | 1 |
| Pearson, TC | 1 |
| Green, AR | 1 |
| Reilly, JT | 1 |
| Harrisoni, G | 1 |
| Randi, ML | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Lengfelder, E | 1 |
| Hehlmann, R | 1 |
| Guilmin, F | 1 |
4 reviews available for pipobroman and Leucocythaemia
| Article | Year |
|---|---|
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero | 2006 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials | 2000 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
2 trials available for pipobroman and Leucocythaemia
| Article | Year |
|---|---|
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cause of Deat | 2003 |
Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Topics: Acute Disease; Bloodletting; Combined Modality Therapy; Humans; Hydroxyurea; Leukemia; Phosphorus Ra | 1993 |
8 other studies available for pipobroman and Leucocythaemia
| Article | Year |
|---|---|
Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Disease Progression; Female; Humans; Leukemia; Ma | 2003 |
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
Topics: Adult; Cause of Death; Drug Evaluation; Female; Humans; Incidence; Leukemia; Longitudinal Studies; M | 2004 |
[Management of polycythaemia with pipobroman].
Topics: Female; Humans; Leukemia; Male; Myeloproliferative Disorders; Pipobroman; Polycythemia; Polycythemia | 1982 |
Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Female; Follow-Up | 1998 |
Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Pipobroman; Polycythemia Vera | 1998 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].
Topics: Aged; Alopecia; Combined Modality Therapy; Cystitis; Erectile Dysfunction; Female; Fever; Follow-Up | 2001 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; L | 1968 |